Tracks how adults with depression respond to common antidepressant medicines
Follows adults with major depressive disorder who take SSRI or SNRI antidepressants.
Plain-language title generated from the registry record
Registry title: Tracking Response to Antidepressants in Advance of Investigational Trials
Key facts
- Where
- Watertown, United StatesSee the site
Where in United States
- Adams ClinicalWatertown, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Adams Clinical
- Trial code
- NCT04748276
- Record updated
- 27 October 2026
- Original description
TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials.Read full original descriptionShow less
Tracking Response to Antidepressants in Advance of Investigational Trials
TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials.
Inclusion: Participant has signed an ICF prior to any study-specific procedures being performed; Participant is male or female of age ≥ 18 years old; Participant has a diagnosis of MDD as confirmed by the MINI semi-structured diagnostic interview and ≥ 14 HAM-D total score; Participant is in good physical health and, in the opinion of the investigator, is a suitable candidate for treatment with an ADT.
Exclusion: Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the opinion of the investigator could pose undue risk to the participant, or compromise the study; Participant has a history of any psychiatric condition other than MDD, which in the opinion of the investigator is primary, or any other psychiatric or neurologic disorder or symptom that could pose undue risk to the participant or compromise the study; Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study; Participant is pregnant, breast-feeding, or planning to become pregnant; A history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic abnormality, which in the opinion of the investigator may impact participant safety or study results; Any participant who represents an acute suicidal risk in the opinion of the investigator.